Search

Your search keyword '"Aravindhan Veerapandiyan"' showing total 9 results
Start Over "Aravindhan Veerapandiyan" Publication Type Magazines
9 results on '"Aravindhan Veerapandiyan"'

1. Researchers from Washington University Report on Findings in Gene Therapy (Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy).

Subjects
DUCHENNE muscular dystrophy, ADVERSE health care events, GENE therapy, RESEARCH personnel, NEUROLOGICAL disorders, FACIOSCAPULOHUMERAL muscular dystrophy
Abstract

A recent study conducted by researchers from Washington University in St. Louis, Missouri, explores the management of adverse events following gene therapy for patients with Duchenne muscular dystrophy (DMD). DMD is a rare neuromuscular disease caused by mutations in the dystrophin gene. The study aims to provide consensus considerations for the evaluation and management of potential treatment-related adverse events (TRAEs) such as vomiting, acute liver injury, myocarditis, and immune-mediated myositis. The interdisciplinary panel of specialists developed these considerations through a modified Delphi process. The research was supported by Sarepta Therapeutics and has been peer-reviewed. [Extracted from the article]

Published
2024

2. University of Wisconsin School of Medicine and Public Health Reports Findings in Pediatrics (Estimate of the incidence of PANDAS and PANS in 3 primary care populations).

Subjects
PANDAS, PRIMARY care, PEDIATRICS, PUBLIC health, PUBLIC schools
Abstract

Madison, Wisconsin, United States, North and Central America, Health and Medicine, Pediatrics Keywords for this news article include: Madison, Wisconsin, Pediatrics, United States, Health and Medicine, North and Central America. Keywords: Madison; Wisconsin; United States; North and Central America; Health and Medicine; Pediatrics EN Madison Wisconsin United States North and Central America Health and Medicine Pediatrics 599 599 1 10/24/23 20231027 NES 231027 2023 OCT 28 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Health and Medicine - Pediatrics is the subject of a report. [Extracted from the article]

Published
2023

3. University of Arkansas for Medical Sciences Reports Findings in Dystonia (Child Neurology: KMT2B-Related Dystonia in a Young Child With Worsening Gait Abnormality).

Subjects
MEDICAL sciences, SCIENCE journalism, MOVEMENT disorders, DYSTONIA, NEUROLOGICAL disorders, NEUROLOGY
Abstract

Little Rock, Arkansas, United States, North and Central America, Child Neurology, Dyskinesias, Dystonia, Health and Medicine, Musculoskeletal Diseases and Conditions, Nervous System Diseases and Conditions, Neurologic Manifestations Keywords: Little Rock; Arkansas; United States; North and Central America; Child Neurology; Dyskinesias; Dystonia; Health and Medicine; Musculoskeletal Diseases and Conditions; Nervous System Diseases and Conditions; Neurologic Manifestations EN Little Rock Arkansas United States North and Central America Child Neurology Dyskinesias Dystonia Health and Medicine Musculoskeletal Diseases and Conditions Nervous System Diseases and Conditions Neurologic Manifestations 413 413 1 04/24/23 20230424 NES 230424 2023 APR 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Nervous System Diseases and Conditions - Dystonia is the subject of a report. [Extracted from the article]

Published
2023

4. New Duchenne Muscular Dystrophy Study Findings Have Been Reported from University of Arkansas for Medical Sciences (Epilepsy Characteristics in Duchenne and Becker Muscular Dystrophies).

Subjects
DUCHENNE muscular dystrophy, BECKER muscular dystrophy, MEDICAL sciences, CENTRAL nervous system diseases, NEUROLOGICAL disorders
Abstract

Atrophic Muscular Disorders, Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Cytoskeletal Proteins, Duchenne Muscular Dystrophy, Dystrophin, Epilepsy, Health and Medicine, Membrane Proteins, Muscle Proteins, Muscular Diseases and Conditions, Muscular Dystrophies, Muscular Dystrophy, Musculoskeletal Diseases and Conditions, Nervous System Diseases and Conditions, Neuromuscular Diseases and Conditions Keywords: Atrophic Muscular Disorders; Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Cytoskeletal Proteins; Duchenne Muscular Dystrophy; Dystrophin; Epilepsy; Health and Medicine; Membrane Proteins; Muscle Proteins; Muscular Diseases and Conditions; Muscular Dystrophies; Muscular Dystrophy; Musculoskeletal Diseases and Conditions; Nervous System Diseases and Conditions; Neuromuscular Diseases and Conditions EN Atrophic Muscular Disorders Brain Diseases and Conditions Central Nervous System Diseases and Conditions Cytoskeletal Proteins Duchenne Muscular Dystrophy Dystrophin Epilepsy Health and Medicine Membrane Proteins Muscle Proteins Muscular Diseases and Conditions Muscular Dystrophies Muscular Dystrophy Musculoskeletal Diseases and Conditions Nervous System Diseases and Conditions Neuromuscular Diseases and Conditions 428 428 1 03/23/23 20230317 NES 230317 2023 MAR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on duchenne muscular dystrophy. [Extracted from the article]

Published
2023

5. REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients.

Subjects
DUCHENNE muscular dystrophy, GENE therapy, NEUROLOGICAL disorders, BLOOD proteins, NEUROMUSCULAR diseases, FACIOSCAPULOHUMERAL muscular dystrophy
Abstract

Antibodies, Pharmaceuticals, Business, Genetics, Neurology, Immunology, Gene Therapy, Bioengineering, Blood Proteins, Regenxbio Inc, Immunoglobulins, Clinical Research, Drugs and Therapies, Health and Medicine, Post-Trial Research, Muscular Dystrophies, Clinical Trials and Studies, Duchenne Muscular Dystrophy, Healthcare Biotechnology Companies, Muscular Diseases and Conditions, Muscular Dystrophy, Musculoskeletal Diseases and Conditions, Nervous System Diseases and Conditions, Neuromuscular Diseases and Conditions, Proteins, Therapy, Atrophic Muscular Disorders Keywords: Antibodies; Pharmaceuticals; Business; Genetics; Neurology; Immunology; Gene Therapy; Bioengineering; Blood Proteins; Regenxbio Inc; Immunoglobulins; Clinical Research; Drugs and Therapies; Health and Medicine; Post-Trial Research; Muscular Dystrophies; Atrophic Muscular Disorders; Clinical Trials and Studies; Duchenne Muscular Dystrophy; Healthcare Biotechnology Companies; Muscular Diseases and Conditions; Muscular Dystrophy; Musculoskeletal Diseases and Conditions; Nervous System Diseases and Conditions; Neuromuscular Diseases and Conditions; Proteins; Therapy EN Antibodies Pharmaceuticals Business Genetics Neurology Immunology Gene Therapy Bioengineering Blood Proteins Regenxbio Inc Immunoglobulins Clinical Research Drugs and Therapies Health and Medicine Post-Trial Research Muscular Dystrophies Atrophic Muscular Disorders Clinical Trials and Studies Duchenne Muscular Dystrophy Healthcare Biotechnology Companies Muscular Diseases and Conditions Muscular Dystrophy Musculoskeletal Diseases and Conditions Nervous System Diseases and Conditions Neuromuscular Diseases and Conditions Proteins Therapy REGENXBIO Inc. (Nasdaq: RGNX) announced that the Phase I/II AFFINITY DUCHENNE(TM) trial of RGX-202 for the treatment of Duchenne muscular dystrophy (Duchenne) is now active and recruiting patients. [Extracted from the article]

Published
2023

7. REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients

Subjects
Duchenne muscular dystrophy -- Care and treatment, Biotechnology industry -- Product development, Gene therapy -- Testing, Recombinant proteins -- Testing, Health
Abstract

2023 FEB 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- REGENXBIO Inc. (Nasdaq: RGNX) announced that the Phase I/II AFFINITY DUCHENNE[TM] trial [...]

Published
2023

8. Investigators from University of Wisconsin Madison Zero in on Spinal Muscular Atrophy (An Expanded Access Program of Risdiplam for Patients With Type 1 or 2 Spinal Muscular Atrophy)

Subjects
Orphan drugs -- Usage, Neurological research, Spinal muscular atrophy -- Drug therapy, Health
Abstract

2022 JUN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Neuromuscular Diseases and Conditions - Spinal Muscular Atrophy have [...]

Published
2022

9. Adjoining Industrial Tallies $10.5 Million

Author

Waldon, George

Subjects
Real estate listings, Business, Business, regional
Abstract

A pair of 61,500-SF flex buildings in west Little Rock weighed in at $10.5 million. CGCCIN2 LLC, led by John Hathaway and John Humphrey Jr., and JTD Midtowne Investments LLC, [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results